## Ning Liu

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5881262/publications.pdf

Version: 2024-02-01

933447 839539 21 354 10 18 h-index citations g-index papers 22 22 22 497 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Hsa-miR-146a-5p modulates androgen-independent prostate cancer cells apoptosis by targeting ROCK1. Prostate, 2015, 75, 1896-1903.	2.3	68
2	Improved outcome of percutaneous radiofrequency ablation in renal cell carcinoma: a retrospective study of intraoperative contrast-enhanced ultrasonography in 73 patients. Abdominal Radiology, 2012, 37, 885-891.	2.1	40
3	TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas. Journal of Experimental and Clinical Cancer Research, 2019, 38, 119.	8.6	32
4	Clinical characteristics of XP11.2 translocation/TFE3 gene fusion renal cell carcinoma: a systematic review and meta-analysis of observational studies. BMC Urology, 2016, 16, 40.	1.4	28
5	Percutaneous radiofrequency ablation for renal cell carcinoma vs. partial nephrectomy: Comparison of long-term oncologic outcomes in both clear cell and non-clear cell of the most common subtype. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 530.e1-530.e6.	1.6	26
6	Renal Cell Carcinoma Associated with $Xp11.2$ Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis. PLoS ONE, 2016, 11, e0166897.	2.5	25
7	Percutaneous radiofrequency ablation with contrast-enhanced ultrasonography for solitary and sporadic renal cell carcinoma in patients with autosomal dominant polycystic kidney disease. World Journal of Surgical Oncology, 2016, 14, 193.	1.9	16
8	Newly Designed Break-Apart and ASPL-TFE3 Dual-Fusion FISH Assay Are Useful in Diagnosing Xp11.2 Translocation Renal Cell Carcinoma and ASPL-TFE3 Renal Cell Carcinoma. Medicine (United States), 2015, 94, e873.	1.0	13
9	Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients. BMC Urology, 2018, 18, 60.	1.4	12
10	PRCC-TFE3 dual-fusion FISH assay: A new method for identifying PRCC-TFE3 renal cell carcinoma in paraffin-embedded tissue. PLoS ONE, 2017, 12, e0185337.	2.5	11
11	Nephron-Sparing Surgery for Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical T1 Stage: A Multicenter Study in China. Annals of Surgical Oncology, 2021, 28, 1238-1246.	1.5	11
12	PPAR $\hat{I}^3$ Alleviates Right Ventricular Failure Secondary to Pulmonary Arterial Hypertension in Rats. International Heart Journal, 2017, 58, 948-956.	1.0	10
13	The positive regulation loop between NRF1 and NONO-TFE3 fusion promotes phase separation and aggregation of NONO-TFE3 in NONO-TFE3 tRCC. International Journal of Biological Macromolecules, 2021, 176, 437-447.	7.5	10
14	Postoperative recurrence of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion. Journal of International Medical Research, 2017, 45, 1287-1296.	1.0	9
15	Does the Fuhrman or World Health Organization/International Society of Urological Pathology Grading System Apply to the $Xp11.2$ Translocation Renal Cell Carcinoma?. American Journal of Pathology, 2018, 188, 929-936.	3.8	9
16	Comparative Clinicopathologic Characteristics and Outcomes of Paediatric and Adult Xp11 Translocation Renal Cell Carcinomas: a Retrospective Multicentre Study in China. Scientific Reports, 2020, 10, 2249.	3.3	9
17	Pseudocapsule of renal cell carcinoma associated with $Xp11.2$ translocation/TFE3 gene fusion: a clue for tumor enucleation?. International Journal of Clinical and Experimental Pathology, 2015, 8, 5403-10.	0.5	9
18	Are tumor-associated micro-angiogenesis and lymphangiogenesis considered as the novel prognostic factors for patients with Xp11.2 translocation renal cell carcinoma?. BMC Cancer, 2020, 20, 1182.	2.6	6

## Ning Liu

#	Article	IF	CITATIONS
19	Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of $Xp11.2$ translocation renal cell carcinoma. Clinical and Translational Medicine, 2022, 12, e797.	4.0	5
20	A new risk-scoring system to predict Xp11.2 translocation renal cell carcinoma in adults. Journal of International Medical Research, 2021, 49, 030006052199766.	1.0	1
21	Molecular Heterogeneity of Xp11.2 Translocation Renal Cell Carcinoma: The Correlation Between Split Signal Pattern in FISH and Prognosis. Cancer Management and Research, 2021, Volume 13, 2419-2431.	1.9	1